US20090186850A1 - Peritoneal dialysis method - Google Patents
Peritoneal dialysis method Download PDFInfo
- Publication number
- US20090186850A1 US20090186850A1 US12/414,312 US41431209A US2009186850A1 US 20090186850 A1 US20090186850 A1 US 20090186850A1 US 41431209 A US41431209 A US 41431209A US 2009186850 A1 US2009186850 A1 US 2009186850A1
- Authority
- US
- United States
- Prior art keywords
- composition
- meq
- atp
- glucose
- peritoneal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Abstract
A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate.
The peritoneal dialysate is safe and causes less peritoneal injuries even when employed in peritoneal dialysis over a long period of time.
Description
- The present invention relates to a preventive or therapeutic agent for peritoneal injuries which may occur during peritoneal dialysis; to a peritoneal dialysate which is safe and causes less peritoneal injuries or other disorders; and to a peritoneal dialysis method using the peritoneal dialysate.
- In an advanced stage of renal failure, body wastes cannot be removed sufficiently, and therefore, blood levels of uremia-related substances such as urea nitrogen (BUN), creatinine (Cr), phosphorus (P), and potassium (K) increase, to thereby induce a variety of symptoms. The symptoms include increased fatigue, shortness of breath, decreased urine volume, edema, loss of appetite, and in addition to these, hypertension, hyperkalemia, and anemia. If left untreated, patients will eventually die. Therefore, patients suffering from uremia must undergo hemodialysis, peritoneal dialysis, or renal transplantation.
- Of these three treatment approaches, peritoneal dialysis has recently come into wide use, for several reasons. Firstly, as compared with hemodialysis, peritoneal dialysis is convenient in that it can be performed at home, requiring neither a special device nor human assistance; peritoneal dialysis is a slow process, and thus can maintain the patient's physical condition stable, without causing low blood pressure or uncomfortable, tired feeling which may otherwise be caused after dialysis; and with peritoneal dialysis, the patient is free from the “lost time” that arises in the case of hemodialysis.
- However, when patients are treated with peritoneal dialysis for a long period of time, they may have a problem of possible functional disorder of the peritoneum, involving hardening of the peritoneum, or peritonitis. This disorder is caused by a high dose of glucose employed in peritoneal dialysis, where the peritoneum is used as a semipermeable membrane, and a dialysate containing glucose at a high concentration is introduced into the intraperitoneal cavity through a catheter indwelled therein, and the high-glucose level dialysate is kept in there for 5 to 6 hours before discharge.
- To solve the problem above, the present invention provides a peritoneal dialysate which causes less peritoneal injuries and can be employed in peritoneal dialysis continuously over a long period of time, and a peritoneal dialysis method using the dialysate.
- The present inventors have focused on peritoneal mesothelial cells lining the peritoneum, and have searched for substances which are capable of preventing peritoneal mesothelial cell injuries caused by high sugar level, and have found that adenosine triphosphate (ATP) or a salt thereof has an effect of preventing peritoneal mesothelial cell injuries, that ATP or a salt thereof thus is useful for a preventive or therapeutic agent for peritoneal injuries, and that a peritoneal dialysate containing ATP or a salt thereof can be employed in peritoneal dialysis for a long period of time, thus completing the present invention.
- Accordingly, the present invention provides a peritoneal dialysate containing ATP or a salt thereof.
- The present invention also provides a preventive or therapeutic agent for peritoneal injuries, the agent containing ATP or a salt thereof as an active ingredient.
- The present invention also provides an agent for treating cell injuries caused by sugar, the agent containing ATP or a salt thereof as an active ingredient.
- The present invention also provides use of ATP or a salt thereof in manufacture of a peritoneal dialysate.
- The present invention also provides use of ATP or a salt thereof in manufacture of a preventive or therapeutic agent for peritoneal injury.
- The present invention also provides use of ATP or a salt thereof in manufacture of an agent for treating cell injuries caused by sugar.
- The present invention also provides a peritoneal dialysis method, characterized by comprising using a dialysate containing ATP or a salt thereof in an effective amount.
- The present invention also provides a therapeutic method for peritoneal injuries, characterized by administering ATP or a salt thereof in an effective amount.
- The present invention also provides a therapeutic method for cell injuries caused by sugar, characterized by administering ATP or a salt thereof in an effective amount.
- According to the present invention, there can be obtained a peritoneal dialysate which is safe and which, after use in peritoneal dialysis for a long period of time, causes less peritoneal injuries.
-
FIG. 1 shows effect of ATP on decrease in the viability of HPMC (human peritoneal mesothelial cells) attributed to glucose (5.8 mM, 75 mM, and 140 mM) (as measured by absorbance); -
FIG. 2 shows effect of adenosine on decrease in the viability of HPMC attributed to glucose (5.8 mM, 75 mM, and 140 mM) (as measured by absorbance); -
FIG. 3 shows effect of an ATP receptor antagonist (Suramin, 10 μM) exerted on the ATP's effect on decrease in the viability, as measured by absorbance, of HPMC attributed to glucose (5.8 mM, 75 mM, and 140 mM); -
FIG. 4 shows effect of an ATP receptor antagonist (Reactive Blue 2, 30 μM) exerted on the ATP's effect on decrease in the viability, as measured by absorbance, of HPMC attributed to glucose (5.8 mM, 75 mM, and 140 mM); and -
FIG. 5 shows effect of an ATP receptor antagonist (PPADS, 10 μM) exerted on the ATP's effect on decrease in the viability, as measured by absorbance, of HPMC attributed to glucose (5.8 mM, 75 mM, and 140 mM). - Adenosine triphosphate (ATP) employed in the present invention has been known to be an energy source for cells. However, it has remained unknown that ATP can function to prevent injury of cells; in particular, peritoneal mesothelial cells, caused by high sugar level, inter alia, glucose. As shown in the Examples below, peritoneal mesothelial cells which had been pretreated with an ATP receptor antagonist prior to a treatment with ATP did not exhibit any preventive effect for peritoneal mesothelial cell injuries. The results indicate that the therapeutic effect of ATP on cell injuries is not attributed to an action of ATP serving as an energy source after being taken into the cells, but rather to an action of ATP exhibited by the mediation of an ATP receptor.
- Preferred examples of the salt of ATP include alkali metal salts such as sodium salts, and alkaline earth metal salts such as magnesium salts and calcium salts.
- The peritoneal dialysate of the present invention contains an effective amount of ATP or a salt thereof. The level of the ATP or a salt thereof in the peritoneal dialysate is preferably 10 to 5,000 μM, more preferably 50 to 3,000 μM, even more preferably 50 to 2,000 μM.
- The peritoneal dialysate of the present invention desirably contains, in addition to ATP or a salt thereof, glucose and electrolytes. The glucose level is preferably 1,000 to 4,000 mg/dL, more preferably 1,200 to 3,600 mg/dL. As the electrolytes, Na+, Ca2+, Mg2+, and Cl− are employed. Preferably, the peritoneal dialysate of the present invention contains Na+ in an amount of 100 to 200 mEq/L, Ca2+ in an amount of 4 to 5 mEq/L, Mg2+ in an amount of 1 to 2 mEq/L, and Cl− in an amount of 80 to 120 mEq/L. Preferably, the peritoneal dialysate of the present invention further contains an organic acid such as lactic acid in an amount of 30 to 50 mEq/L. Preferably, the osmotic pressure of the peritoneal dialysate is adjusted to 300 to 700 mOsm/L. The balance is water.
- The peritoneal dialysate of the present invention containing ATP or a salt thereof can prevent peritoneal injuries and cell injuries; in particular, peritoneal mesothelial cell injuries, which may otherwise be caused by high sugar level. Examples of the peritoneal injuries include peritonitis, sclerotic encysted peritonitis, intractable prolonged peritonitis, and general peritonitis. However, the preventive or therapeutic agent for peritoneal injury or the therapeutic agent for cell injury according to the present invention may be employed, instead of being in the form of peritoneal dialysate, in drug forms for, for example, peroral administration, intravenous administration, intramuscular administration, and local administration. Drug formulations suitable for these administration routes can be produced by adding one or more pharmacologically acceptable carriers to the agent and then treating the mixture through a routine process known to those skilled in the art.
- When an oral solid drug product is prepared, ATP or a salt thereof is mixed with an excipient (and, if necessary, one or more additives such as a binder, a disintegrant, a lubricant, a coloring agent, a sweetening agent, and a flavoring agent), and the resultant mixture is processed through a routine method, to thereby produce an oral solid drug product such as tablets, coated tablets, granules, powder, or capsules. Additives may be those generally employed in the art. Examples of the excipient include lactate, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and silicic acid; examples of the binder include water, ethanol, propanol, simple syrup, glucose solution, starch solution, liquefied gelatin, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate, and polyvinyl pyrrolidone; examples of the disintegrant include dried starch, sodium arginate, powdered agar, sodium hydrogencarbonate, calcium carbonate, sodium lauryl sulfate, monoglyceryl stearate, and lactose; examples of the lubricant include purified talc, stearic acid salts, borax, and polyethylene glycol; and examples of the sweetening agent include sucrose, orange peel, citric acid, and tartaric acid.
- When a liquid drug product for oral administration is prepared, ATP or a salt thereof is mixed with an additive such as a sweetening agent, a buffer, a stabilizer, or a flavoring agent, and the resultant mixture is processed through a routine method, to thereby produce an orally administered liquid drug product such as an internal solution medicine, syrup, or elixir. Examples of the sweetening agent include vanillin; examples of the buffer include sodium citrate; and examples of the stabilizer include tragacanth, acacia, and gelatin.
- When an injection product is prepared, ATP or a salt thereof is mixed with an additive such as a pH regulator, a buffer, a stabilizer, an isotonicity agent, or a local anesthetic, and the resultant mixture is processed through a routine method, to thereby produce an injection for subcutaneous injection, intramuscular injection, or intravenous injection. Examples of the pH regulator or buffer include sodium citrate, sodium acetate, and sodium phosphate; examples of the stabilizer include sodium pyrosulfite, EDTA, thioglycollic acid, and thiolactic acid; examples of the local anesthetic include procaine hydrochloride and lidocaine hydrochloride; and examples of the isotonicity agent include sodium chloride and glucose.
- The dose of the drug (N.B. not applicable to the case of peritoneal dialysate) of the present invention differs depending on the age, body weight, and conditions of the patient, and the manner and frequency of administration, etc. The daily dose of ATP for an adult is typically 1 to 1,000 mg, and the drug is preferably administered perorally or intravenously once a day or several times a day in a divided manner.
- The peritoneal dialysate may be employed in accordance with a conventional peritoneal dialysis method. Specifically, a catheter is introduced into the peritoneal cavity of a patient suffering a renal disease, and a dialysate (typically 1.5 to 2.0 L) containing ATP is intraperitoneally administered to the patient via the catheter. Alternatively, an ATP-containing glucose solution having a physiological glucose level is administered, and, thereafter, a conventional dialysate (such as a solution containing high level glucose) is administered. The thus-infused dialysate or solution is maintained for about five to six hours and then discharged. Typically, the procedure is repeated three to five times a day. The physiological glucose level is 0.08 to 0.16% (w/v).
- The present invention will next be described in detail by way of examples, which should not be construed as limiting the invention thereto.
- Peritoneal mesothelial cells (HPMC) were preincubated for three hours in culture media (M199) containing ATP (0, 10, 100, and 1,000 μM). The cells were washed with an HPMC culture medium (saline buffer) and then incubated for eight hours in culture media (M199) containing glucose at three different levels (5.8 mM, 75 mM, and 140 mM). HPMC viability was obtained through cell counting (WST-1).
- The results are shown in
FIG. 1 . When HPMC was preincubated with the culture media containing no ATP, the viability of the HPMC decreased as the glucose level increased, whereas when HPMC was preincubated with the culture media containing ATP, decrease in viability caused by high level glucose was significantly alleviated. - Instead of ATP, adenosine, which is a metabolite of ATP, was employed to study the effect of adenosine on decrease in HPMC viability caused by high level glucose.
- The results are shown in
FIG. 2 . Adenosine exhibited no effect of alleviating decrease in HPMC viability, as shown in the case of ATP. - Prior to the step of preincubation with ATP-containing culture media in the procedure of Example 1, HPMC were preincubated for 30 minutes with each of the following selective ATP receptor antagonists: (1) Suramin (P2X, P2Y receptor antagonist; 10 μM), (2) Reactive Blue 2 (P2Y receptor antagonist; 30 μM), and (3) PPADS (P2X receptor antagonist; 10 μM). Thereafter, the test was performed as described in Example 1.
- The results are shown in
FIGS. 3 , 4, and 5. When the HPMC was treated with ATP receptor antagonist, ATP exhibited no effect of alleviating reduction in HPMC viability. - The results obtained in Example 1 indicate that ATP has an effect of significantly preventing peritoneal mesothelial cell injuries caused by high glucose level. The results obtained in Examples 2 and 3 reveal that this effect of ATP is not attributed to an action of ATP serving as an energy source after being taken into the cells, but rather to a direct action of ATP exhibited by the mediation of P2 receptors.
- To each of three dialysates containing glucose (1.36, 2.27, and 3.86%) are added sodium chloride, sodium lactate, calcium chloride, magnesium chloride, etc. so as to attain conventional compositional proportions, and ATP is added so that the resultant mixture attains an ATP level of 50 to 2,000 μM.
- To a glucose solution having physiological glucose level (0.1%) are added sodium chloride, sodium lactate, calcium chloride, magnesium chloride, etc. so as to attain conventional compositional proportions, and ATP is added so that the resultant mixture attains an ATP level of 50 to 2,000 μM.
Claims (21)
1.-20. (canceled)
21. A composition comprising water, glucose, electrolytes, and adenosine triphosphate or a salt thereof in a form suitable for use as a pertioneal dialysate.
22. The composition of claim 21 , which has an osmotic pressure of 300 to 700 mOsm/L.
23. The composition of claim 21 , which contains glucose in at a concentration of 1,000 to 4,000 mg/dL.
24. The composition of claim 21 , which contains glucose in at a concentration of 1,200 to 3,600 mg/dL.
25. The composition of claim 21 , which contains Na+, Ca2+, Mg2+ and Cl− as electrolytes.
26. The composition of claim 21 , which contains as electrolytes 100-200 mEq/L Na+, 4-5 mEq/L Ca2+, 1-2 mEq/L Mg2+ and 80-120 mEq/L Cl−.
27. The composition of claim 21 , which contains 10-5,000 μM ATP or a salt thereof.
28. The composition of claim 21 , which contains 50-2,000 μM ATP or a salt thereof.
29. The composition of claim 21 , further comprising at least one organic acid in an amount ranging from 30-50 mEq/L.
30. The composition of claim 21 , further comprising lactic acid in an amount ranging from 30-50 mEq/L.
31. The composition of claim 21 , which has an osmotic pressure of 300 to 700 mOsm/L, and which contains:
1,000 to 4,000 mg/dL glucose,
100-200 mEq/L Na+, 4-5 mEq/L Ca2+, 1-2 mEq/L Mg2+ and 80-120 mEq/L Cl− as electrolytes,
10-5,000 μM ATP or a salt thereof, and optionally
30-50 mEq/L of at least one organic acid.
32. A peritoneal dialysis method comprising administering into the peritoneum of a subject in need thereof an effective amount of the composition of claim 21 .
33. The method of claim 32 , wherein the composition is administered intraperitoneally via a catheter implanted in the peritoneal cavity.
34. The method of claim 32 , further comprising administering a dialysate containing a level of glucose above a physiological level of glucose
wherein said dialyzate is administered after administering said composition and wherein said composition contains a physiological level of glucose ranging from 0.08 to 0.16% (w/v).
35. The method of claim 32 , wherein the subject has a renal disease.
36. The method of claim 32 , wherein said subject has cell injuries caused by exposure to high levels of sugar.
37. The method of claim 32 , wherein said subject has peritoneal mesothelial cell injuries caused by exposure to high levels of sugar.
38. The method of claim 32 , wherein said subject has hardening of the peritoneum or peritonitis.
39. The method of claim 32 , wherein said subject has sclerotic encysted peritonitis or intractable prolonged peritonitis.
40. A peritoneal dialysis method comprising:
administering into the peritoneum of a subject in need thereof an effective amount of a dialysate comprising water, glucose, electrolytes; and
administering a separate amount of adenosine triphosphate or a salt thereof, which is optionally administered orally, intravenously, intramuscularly, or locally.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/414,312 US20090186850A1 (en) | 2002-11-21 | 2009-03-30 | Peritoneal dialysis method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42798002P | 2002-11-21 | 2002-11-21 | |
US10/533,538 US8222229B2 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
PCT/JP2003/014790 WO2004045679A1 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
US12/414,312 US20090186850A1 (en) | 2002-11-21 | 2009-03-30 | Peritoneal dialysis method |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/533,538 Continuation US8222229B2 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
PCT/JP2003/014790 Continuation WO2004045679A1 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090186850A1 true US20090186850A1 (en) | 2009-07-23 |
Family
ID=32326623
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/533,538 Expired - Fee Related US8222229B2 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
US12/414,312 Abandoned US20090186850A1 (en) | 2002-11-21 | 2009-03-30 | Peritoneal dialysis method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/533,538 Expired - Fee Related US8222229B2 (en) | 2002-11-21 | 2003-11-20 | Peritoneal dialysis method |
Country Status (11)
Country | Link |
---|---|
US (2) | US8222229B2 (en) |
EP (1) | EP1563858A4 (en) |
JP (1) | JP4463687B2 (en) |
KR (1) | KR101057082B1 (en) |
CN (1) | CN1713926B (en) |
AU (2) | AU2003284594B2 (en) |
CA (1) | CA2506704C (en) |
HK (1) | HK1082441A1 (en) |
NZ (1) | NZ539796A (en) |
RU (1) | RU2353400C2 (en) |
WO (1) | WO2004045679A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9757196B2 (en) | 2011-09-28 | 2017-09-12 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10245105B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Electroporation with cooling to treat tissue |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10470822B2 (en) | 2008-04-29 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11453873B2 (en) | 2008-04-29 | 2022-09-27 | Virginia Tech Intellectual Properties, Inc. | Methods for delivery of biphasic electrical pulses for non-thermal ablation |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11707629B2 (en) | 2009-05-28 | 2023-07-25 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235589B2 (en) * | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
EP2129370B1 (en) | 2007-03-02 | 2012-11-21 | Zytoprotec Gmbh | Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue |
TW200936619A (en) | 2007-11-15 | 2009-09-01 | Univation Tech Llc | Polymerization catalysts, methods of making, methods of using, and polyolefin products made therefrom |
ES2365429B1 (en) * | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | SOLUTION FOR PERITONEAL DIALYSIS |
WO2012025602A1 (en) | 2010-08-26 | 2012-03-01 | Vib Vzw | Insect binding antibodies |
BR112013012545B1 (en) | 2010-11-30 | 2020-04-14 | Univation Tech Llc | catalyst composition, production process of a catalyst composition and polymerization process |
EP2646480B1 (en) | 2010-11-30 | 2016-04-13 | Univation Technologies, LLC | Processes for the polymerization of olefins with extracted metal carboxylate salts |
CN103347905B (en) | 2010-12-22 | 2015-12-16 | 尤尼威蒂恩技术有限责任公司 | For the additive of bed polyolefin polymerization process |
CN103619372A (en) | 2011-03-23 | 2014-03-05 | 纳科斯达格医药股份有限公司 | Peritoneal dialysis system, device and method |
US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
RU2598023C2 (en) | 2011-05-13 | 2016-09-20 | Юнивейшн Текнолоджиз, Ллк | Spray drying-obtained catalyst compositions and polymerisation methods using same |
EP2750797B1 (en) | 2011-11-08 | 2020-04-01 | Univation Technologies, LLC | Methods of preparing a catalyst system |
CN105189566A (en) | 2013-01-30 | 2015-12-23 | 尤尼威蒂恩技术有限责任公司 | Processes for making catalyst compositions having improved flow |
CA2943378C (en) | 2014-04-02 | 2023-09-12 | Univation Technologies, Llc | Continuity compositions and methods of making and using the same |
CN107107433B (en) | 2015-01-21 | 2019-09-13 | 尤尼威蒂恩技术有限责任公司 | Method for the gel reduction in polyolefin |
US10471641B2 (en) | 2015-01-21 | 2019-11-12 | Univation Technologies, Llc | Methods for controlling polymer chain scission |
SG11201707037TA (en) | 2015-03-10 | 2017-09-28 | Univation Tech Llc | Spray dried catalyst compositions, methods for preparation and use in olefin polymerization processes |
US10533063B2 (en) | 2015-04-20 | 2020-01-14 | Exxonmobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
US10519256B2 (en) | 2015-04-27 | 2019-12-31 | Univation Technologies, Llc | Supported catalyst compositions having improved flow properties and preparation thereof |
DE102015007842A1 (en) * | 2015-06-18 | 2016-12-22 | Fresenius Medical Care Deutschland Gmbh | dialysis solution |
WO2018151903A1 (en) | 2017-02-20 | 2018-08-23 | Exxonmobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
CN111094366B (en) | 2017-08-04 | 2022-06-24 | 埃克森美孚化学专利公司 | Polyethylene compositions and films made therefrom |
AU2019228526B2 (en) | 2018-02-28 | 2021-11-25 | Nxstage Medical, Inc. | Fluid preparation and treatment devices, methods, and systems |
US11414436B2 (en) | 2018-04-26 | 2022-08-16 | Exxonmobil Chemical Patents Inc. | Non-coordinating anion type activators containing cation having large alkyl groups |
WO2019246069A1 (en) | 2018-06-19 | 2019-12-26 | Exxonmobil Chemical Patents Inc. | Polyethylene compositions and films prepared therefrom |
WO2021119089A1 (en) | 2019-12-11 | 2021-06-17 | Exxonmobil Chemical Patents Inc. | Processes for introduction of liquid activators in olefin polymerization reactions |
WO2021194831A1 (en) | 2020-03-25 | 2021-09-30 | Exxonmobil Chemical Patents Inc. | Alkylation of transition metal coordination catalyst complexes |
WO2021262838A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | Copolymers composed of ethylene, a-olefin, non-conjugated diene, and substituted styrene and articles therefrom |
WO2021262842A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | COPOLYMERS OF ETHYLENE, α-OLEFIN, NON-CONJUGATED DIENE, AND ARYL-SUBSTITUTED CYCLOALKENE, METHODS TO PRODUCE, BLENDS, AND ARTICLES THEREFROM |
CN116209683A (en) | 2020-08-10 | 2023-06-02 | 埃克森美孚化学专利公司 | Method for delivering non-aromatic solutions to a polymerization reactor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871477A (en) * | 1995-11-28 | 1999-02-16 | Material Engineering Technology Laboratory, Incorporated | Medical container with electrolyte solution stored therein |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
US5679650A (en) | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
JP3083156B2 (en) | 1993-02-10 | 2000-09-04 | アストラ・フアーマシユウテイカルズ・リミテツド | N-alkyl-2-substituted ATP analogs |
US5547942A (en) * | 1994-01-04 | 1996-08-20 | Rapaport; Eliezer | Method of treatment of diabetes mellitus by administration of adenosine 5'-t |
JPH09143063A (en) * | 1995-11-22 | 1997-06-03 | Kose Corp | Composition suitable for external use |
ATE270096T1 (en) * | 1997-08-22 | 2004-07-15 | Shimizu Pharma | PREPARATION CONTAINING GLUCOSE |
EP1108434B1 (en) * | 1998-08-24 | 2014-05-14 | Kurokawa, Kiyoshi | Drugs for relieving carbonyl stress and peritoneal dialysates |
US6309673B1 (en) * | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
-
2003
- 2003-11-20 JP JP2004553210A patent/JP4463687B2/en not_active Expired - Fee Related
- 2003-11-20 NZ NZ539796A patent/NZ539796A/en not_active IP Right Cessation
- 2003-11-20 EP EP03774083A patent/EP1563858A4/en not_active Withdrawn
- 2003-11-20 RU RU2005119309/15A patent/RU2353400C2/en not_active IP Right Cessation
- 2003-11-20 CA CA2506704A patent/CA2506704C/en not_active Expired - Fee Related
- 2003-11-20 US US10/533,538 patent/US8222229B2/en not_active Expired - Fee Related
- 2003-11-20 WO PCT/JP2003/014790 patent/WO2004045679A1/en active Application Filing
- 2003-11-20 AU AU2003284594A patent/AU2003284594B2/en not_active Ceased
- 2003-11-20 KR KR1020057008224A patent/KR101057082B1/en not_active IP Right Cessation
- 2003-11-20 CN CN2003801036528A patent/CN1713926B/en not_active Expired - Fee Related
-
2006
- 2006-03-13 HK HK06103148.9A patent/HK1082441A1/en not_active IP Right Cessation
-
2008
- 2008-12-09 AU AU2008255178A patent/AU2008255178B2/en not_active Ceased
-
2009
- 2009-03-30 US US12/414,312 patent/US20090186850A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871477A (en) * | 1995-11-28 | 1999-02-16 | Material Engineering Technology Laboratory, Incorporated | Medical container with electrolyte solution stored therein |
Non-Patent Citations (3)
Title |
---|
Shukolyukov et al. (Mitokohondrii, Mol. Mekh. Ferment. Reakts., Mater. Vses. Simp. Biokhim. Mitokhondrii, 6th (1972), Meeting Date 1970, 189-93. Editor (s): Severin, S. E. "Nauka": Moscow, USSR) (Abstract sent). * |
Yurzhenko ("Parenteral nutrition in the program of therapy of diffuse peritonitis (Russian)", XP002597104, Elsevier Science Publishers, Amsterdam, NL, 1973, Vol. 18, No. 7, pp. 36-38, Cited by Applicant IDS filed September 23, 2010; English Translation). * |
Yurzhenko V P, "Parenteral nutrition in the program of therapy of diffuse peritonitis (Russian)", XP002597104, ElsevierScience Publishers, Amsterdam, NL, 1973, Vol. 18, No. 7, pp. 36-38 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10828085B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US11890046B2 (en) | 2008-04-29 | 2024-02-06 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10959772B2 (en) | 2008-04-29 | 2021-03-30 | Virginia Tech Intellectual Properties, Inc. | Blood-brain barrier disruption using electrical energy |
US11737810B2 (en) | 2008-04-29 | 2023-08-29 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using electroporation |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10245105B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Electroporation with cooling to treat tissue |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10286108B2 (en) | 2008-04-29 | 2019-05-14 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US11655466B2 (en) | 2008-04-29 | 2023-05-23 | Virginia Tech Intellectual Properties, Inc. | Methods of reducing adverse effects of non-thermal ablation |
US11607271B2 (en) | 2008-04-29 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US11453873B2 (en) | 2008-04-29 | 2022-09-27 | Virginia Tech Intellectual Properties, Inc. | Methods for delivery of biphasic electrical pulses for non-thermal ablation |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US10537379B2 (en) | 2008-04-29 | 2020-01-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10470822B2 (en) | 2008-04-29 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10828086B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US11952568B2 (en) | 2008-04-29 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of biphasic electrical pulses for non-thermal ablation |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US11707629B2 (en) | 2009-05-28 | 2023-07-25 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US9757196B2 (en) | 2011-09-28 | 2017-09-12 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US11779395B2 (en) | 2011-09-28 | 2023-10-10 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
US11957405B2 (en) | 2013-06-13 | 2024-04-16 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11406820B2 (en) | 2014-05-12 | 2022-08-09 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US11903690B2 (en) | 2014-12-15 | 2024-02-20 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
Also Published As
Publication number | Publication date |
---|---|
US20060019925A1 (en) | 2006-01-26 |
RU2005119309A (en) | 2006-01-20 |
KR20050075381A (en) | 2005-07-20 |
HK1082441A1 (en) | 2006-06-09 |
EP1563858A1 (en) | 2005-08-17 |
WO2004045679A1 (en) | 2004-06-03 |
JPWO2004045679A1 (en) | 2006-03-16 |
JP4463687B2 (en) | 2010-05-19 |
EP1563858A4 (en) | 2010-09-29 |
AU2008255178B2 (en) | 2010-07-08 |
CN1713926A (en) | 2005-12-28 |
US8222229B2 (en) | 2012-07-17 |
CN1713926B (en) | 2010-12-22 |
CA2506704C (en) | 2013-06-25 |
AU2003284594A1 (en) | 2004-06-15 |
CA2506704A1 (en) | 2004-06-03 |
AU2008255178A1 (en) | 2009-01-08 |
AU2003284594B2 (en) | 2009-01-15 |
KR101057082B1 (en) | 2011-08-16 |
RU2353400C2 (en) | 2009-04-27 |
NZ539796A (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8222229B2 (en) | Peritoneal dialysis method | |
EP2322236B1 (en) | Bicarbonate-based solutions for dialysis therapies | |
Cowe et al. | Neonatal convulsions caused by withdrawal from maternal clomipramine. | |
Illies et al. | Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1 | |
EP1753437B1 (en) | Bicarbonate-based peritoneal dialysis solutions | |
US20060128658A1 (en) | Biocompatible dialysis fluids containing icodextrins | |
Fassler et al. | Magnesium toxicity as a cause of hypotension and hypoventilation: occurrence in patients with normal renal function | |
US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
Engle et al. | The use of furosemide in the treatment of edema in infants and children | |
Umstead et al. | Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction | |
TW200800237A (en) | Sterilized peritoneal dialysis solutions containing heparin | |
RU2412701C2 (en) | Method of reducing intolerance to antituberculous preparations | |
EP0931548A2 (en) | Antifibrotic agent | |
Shoda et al. | Hiromichi Suzuki, Tsutomu Inoue, Kazuhiro Kobayashi | |
Steiner | Antihypertensive drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |